BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/21/2020 4:02:08 PM | Browse: 676 | Download: 1529
 |
Received |
|
2020-04-10 06:52 |
|
Peer-Review Started |
|
2020-04-10 06:52 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2020-04-26 21:15 |
|
Revised |
|
2020-07-12 06:58 |
|
Second Decision |
|
2020-07-21 09:28 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2020-07-26 21:30 |
|
Articles in Press |
|
2020-07-26 21:30 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2020-08-03 19:40 |
|
Typeset the Manuscript |
|
2020-09-11 11:43 |
|
Publish the Manuscript Online |
|
2020-09-21 16:02 |
| ISSN |
1948-5182 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Prospective Study |
| Article Title |
Sofosbuvir plus ribavirin is tolerable and effective even in elderly patients 75-years-old and over
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Hideyuki Tamai, Naoki Shingaki, Yoshiyuki Ida, Ryo Shimizu, Shuya Maeshima, Junpei Okamura, Akira Kawashima, Taisei Nakao, Takeshi Hara, Hiroyoshi Matsutani, Izumi Nishikawa and Katsuhiko Higashi |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Hideyuki Tamai, MD, PhD, Director, Director, Department of Hepatology, Wakayama Rosai Hospital, 93-1 Kinomoto, Wakayama 6408505, Japan. hdy-tamai@wakayamah.johas.go.jp |
| Key Words |
Hepatitis C virus; Genotype 2; Sofosbuvir; Ribavirin; Elderly patients; Cirrhosis |
| Core Tip |
This was a multicenter post-marketing prospective cohort study of sofosbuvir plus ribavirin therapy for patients with genotype 2 hepatitis C virus in a real-world clinical setting. Combination therapy using sofosbuvir plus ribavirin was tolerable and highly effective even in elderly patients 75 years old. |
| Publish Date |
2020-09-21 16:02 |
| Citation |
Tamai H, Shingaki N, Ida Y, Shimizu R, Maeshima S, Okamura J, Kawashima A, Nakao T, Hara T, Matsutani H, Nishikawa I, Higashi K. Sofosbuvir plus ribavirin is tolerable and effective even in elderly patients 75-years-old and over. World J Hepatol 2020; 12(9): 672-684 |
| URL |
https://www.wjgnet.com/1948-5182/full/v12/i9/672.htm |
| DOI |
https://dx.doi.org/ 10.4254/wjh.v12.i9.672 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
